The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome.
Iason PsilopatisKleio VrettouEleni NousiopoulouKostantinos PalamarisStamatios TheocharisPublished in: Journal of clinical medicine (2023)
Polycystic ovary syndrome (PCOS) constitutes the most common endocrine disorder in women of reproductive age. Patients usually suffer from severe menstrual irregularities, skin conditions, and insulin resistance-associated health conditions. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor proteins that regulate gene expression. In order to investigate the role of PPARs in the pathophysiology of PCOS, we conducted a literature review using the MEDLINE and LIVIVO databases and were able to identify 74 relevant studies published between 2003 and 2023. Different study groups reached contradictory conclusions in terms of PPAR expression in PCOS. Interestingly, numerous natural agents were found to represent a novel, potent anti-PCOS treatment alternatives. In conclusion, PPARs seem to play a significant role in PCOS.
Keyphrases
- polycystic ovary syndrome
- insulin resistance
- gene expression
- adipose tissue
- metabolic syndrome
- high fat diet
- skeletal muscle
- end stage renal disease
- type diabetes
- poor prognosis
- public health
- newly diagnosed
- high fat diet induced
- chronic kidney disease
- ejection fraction
- early onset
- peritoneal dialysis
- healthcare
- randomized controlled trial
- binding protein
- climate change
- case report
- wound healing
- replacement therapy
- smoking cessation
- deep learning